Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130557 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
A Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 536
- Enrollment target
- 20
- Study locations
NCT02130557: Completed Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, sponsored by Pfizer.
NCT02130557 is a Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive that has completed, run by Pfizer. The registered enrollment target is 536 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130557, a Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 536 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
Primary Outcome
MMR was defined as a ratio of breakpoint cluster region to abelson (BCR-ABL/ABL) less than or equal to (\<=) 0.1 percent (%) on the international scale (IS) (greater than or equal to \[\>=\] 3 log reduction from standardized baseline in ratio of BCR-ABL to ABL transcripts \[\>=3000 ABL required\]) by quantitative reverse transcriptase polymerase chain reaction (RT-qPCR). The percentage of participants with MMR at Month 12 are reported.
Conditions Studied
Interventions
- DRUG Bosutinib
- DRUG Imatinib
Study Locations (20)
Idaho
- Saint Alphonsus Regional Medical Center, Cancer Care Center - Boise
- Saint Alphonsus Regional Medical Center - Boise
- Saint Alphonsus Caldwell Cancer Care Center - Caldwell
- Saint Alphonsus Medical Center Nampa - Nampa
Louisiana
- Cancer Center of Acadiana at Lafayette General Medical Center - Lafayette
- Lafayette General Medical Center - Lafayette
- LSU Health Sciences Center-Shreveport - Shreveport
- University Health Shreveport - Shreveport
Georgia
- Emory University Hospital - Atlanta
- The Emory Clinic - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Illinois Cancer Center - Chicago
- John H. Stroger, Jr. Hospital of Cook County - Chicago
Indiana
- Indiana Blood and Marrow Transplantation - Indianapolis
- PHARMACY Department Franciscan St. Francis Health ATTN:Jill Leslie, Pharm D - Indianapolis
Massachusetts
- University of Massachusetts Memorial Medical Center, ONC/Research Pharmacy - Worcester
- University of Massachusetts Memorial Medical Center - Worcester
California
- Pacific Cancer Medical Center, Inc. - Anaheim
Hawaii
- Kaiser Permanente Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 536 participants |
| Start Date | 2014-07-15 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 3 |
What the finished NCT02130557 record still lists
NCT02130557 is an interventional study that assigns participants to a tested intervention. The registered 536 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive appearing as the primary indexed condition, and to 2 interventions - of which Bosutinib is the first listed.
NCT02130557 names 20 study sites across 9 states, led by Idaho, Louisiana, Georgia.
Frequently Asked Questions
What is clinical trial NCT02130557 about?
NCT02130557 is a clinical study titled "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
What is the current status of trial NCT02130557?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 536 participants. The study started on 2014-07-15. Estimated completion is 2020-04-17.
What conditions does trial NCT02130557 study?
This clinical trial studies the following conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.
What interventions are being tested in trial NCT02130557?
The interventions under investigation include: Bosutinib (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT02130557?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130557 being conducted?
This trial has 20 study locations across California, Georgia, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02130557's enrollment target sits among peer trials
536 702nd of 2000 higher than 1,299 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI